Overview Ursodiol Tablets 500 mg Under Fasting Conditions Status: Completed Trial end date: 2007-01-01 Target enrollment: Participant gender: Summary The objective of this study was to evaluate the comparative bioavailability between Ursodiol 500 mg Tablets (test) and Urso Forte™ 500 mg Tablets (reference) after a single-dose in healthy subjects under fasting conditions. Phase: Phase 1 Details Lead Sponsor: Teva Pharmaceuticals USATreatments: Ursodeoxycholic Acid